AIM ImmunoTech Inc
AIM3.060USD
+0.230+8.12%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
221.20MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über AIM ImmunoTech Inc Unternehmen
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Unternehmensinformationen
BörsenkürzelAIM
Name des UnternehmensAIM ImmunoTech Inc
IPO-datumJul 12, 1996
CEOMr. Thomas K. Equels, Esq., J.D.
Anzahl der mitarbeiter21
WertpapierartOrdinary Share
GeschäftsjahresendeJul 12
Addresse2117 Sw Highway 484
StadtOCALA
BörseNYSE American Consolidated
LandUnited States of America
Postleitzahl32801
Telefon13524487797
Websitehttps://aimimmuno.com/
BörsenkürzelAIM
IPO-datumJul 12, 1996
CEOMr. Thomas K. Equels, Esq., J.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.88K
+0.54%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+60.53%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
+31.96%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
+232.64%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.88K
+0.54%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+60.53%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
+31.96%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
+232.64%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 12
Aktualisiert: Sat, Jul 12
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Equels (Thomas K)
1.41%
The Vanguard Group, Inc.
0.88%
Kellner (Theodore D)
0.71%
Deutsch (Todd A)
0.62%
BlackRock Institutional Trust Company, N.A.
0.25%
Other
96.12%
Aktionäre
Aktionäre
Anteil
Equels (Thomas K)
1.41%
The Vanguard Group, Inc.
0.88%
Kellner (Theodore D)
0.71%
Deutsch (Todd A)
0.62%
BlackRock Institutional Trust Company, N.A.
0.25%
Other
96.12%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
12.10%
Investment Advisor
4.36%
Investment Advisor/Hedge Fund
1.03%
Hedge Fund
0.74%
Venture Capital
0.11%
Other
81.65%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
68
140.24K
18.35%
-21.39K
2025Q1
83
99.85K
13.13%
-1.64M
2024Q4
79
10.59M
16.61%
-4.59M
2024Q3
75
14.47M
24.79%
+767.12K
2024Q2
74
13.00M
23.76%
+4.07M
2024Q1
77
8.58M
17.30%
-354.68K
2023Q4
77
8.35M
17.07%
-576.60K
2023Q3
80
8.49M
17.46%
-718.46K
2023Q2
77
5.43M
11.23%
-869.40K
2023Q1
81
5.73M
11.83%
-1.19M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Equels (Thomas K)
38.88K
5.09%
+210.00
+0.54%
Jun 13, 2025
The Vanguard Group, Inc.
24.44K
3.2%
+4.56K
+22.91%
Mar 31, 2025
Kellner (Theodore D)
19.70K
2.58%
+19.68K
+196850.00%
Apr 11, 2025
Deutsch (Todd A)
17.16K
2.25%
--
--
Dec 19, 2024
BlackRock Institutional Trust Company, N.A.
6.98K
0.91%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
5.31K
0.7%
+673.00
+14.50%
Mar 31, 2025
Mitchell (William M)
5.22K
0.68%
+1.97K
+60.53%
Apr 11, 2025
Rodino (Peter W III)
4.02K
0.53%
+5.00
+0.12%
Apr 04, 2025
Appelrouth (Stewart L.)
3.89K
0.51%
+670.00
+20.82%
Dec 31, 2024
Renaissance Technologies LLC
3.18K
0.42%
+575.00
+22.07%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 03, 2025
Merger
100<1
Datum
Art
Verhältnis
Mar 03, 2025
Merger
100<1
